Wolff AC, et al. HER2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary. J Oncol Pract. 2018;14(7):437–41.

Article  PubMed  Google Scholar 

Saini KS, et al. Beyond trastuzumab: new treatment options for HER2-positive breast cancer. Breast. 2011;20(Suppl 3):S20–7.

Article  PubMed  Google Scholar 

Capelan M, et al. Pertuzumab: new hope for patients with HER2-positive breast cancer. Ann Oncol. 2013;24(2):273–82.

Article  CAS  PubMed  Google Scholar 

Moreno-Aspitia A, et al. Updated results from the international phase III ALTTO trial (BIG 2–06/Alliance N063D). Eur J Cancer. 2021;148:287–96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Modi S, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saini KS, et al. Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics. Expert Opin Biol Ther. 2021;21(7):945–62.

Article  CAS  PubMed  Google Scholar 

Tarantino P, et al. HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol. 2020;38(17):1951–62.

Article  CAS  PubMed  Google Scholar 

National Comprehensive Cancer Network. Breast Cancer (Version 4.2022). December 5, 2022]; Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.

Tarantino P, et al. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann Oncol. 2023;34(8):645–59.

Article  CAS  PubMed  Google Scholar 

Jones, C., SABCS 2022: The Uncharted Territory of HER2-low Breast Cancer 2023: American Association for Cancer Research.

Popović M, et al. HER2 Low breast cancer: a new subtype or a Trojan for cytotoxic drug delivery? Int J Mol Sci. 2023;24(9):8206.

Article  PubMed  PubMed Central  Google Scholar 

Schettini F, et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer. 2021;7(1):1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tarantino P, et al. Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer. JAMA Oncol. 2022;8(8):1177–83.

PubMed  PubMed Central  Google Scholar 

Denkert C, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021;22(8):1151–61.

Article  CAS  PubMed  Google Scholar 

Peiffer DS, et al. Clinicopathologic characteristics and prognosis of ERBB2-low breast cancer among patients in the National Cancer Database. JAMA Oncol. 2023;9(4):500–10.

Article  PubMed  PubMed Central  Google Scholar 

Miglietta F, et al. Evolution of HER2-low expression from primary to recurrent breast cancer. NPJ Breast Cancer. 2021;7(1):137.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tarantino P, et al. Evolution of low HER2 expression between early and advanced-stage breast cancer. Eur J Cancer. 2022;163:35–43.

Article  CAS  PubMed  Google Scholar 

Bardia A, Viale G. HER2-low breast cancer-diagnostic challenges and opportunities for insights from ongoing studies: a podcast. Target Oncol. 2023;18(3):313–9.

Article  PubMed  PubMed Central  Google Scholar 

Fernandez AI, et al. Examination of low ERBB2 protein expression in breast cancer tissue. JAMA Oncol. 2022;8(4):1–4.

Article  PubMed  PubMed Central  Google Scholar 

Mosele F. et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nature Medicine, 2023.

AstraZeneca. A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's choice chemotherapy in HER2-low, hormone receptor positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting (DESTINY-Breast06). August 2, 2023 [cited 2023 August 2]; Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04494425.

Wolff AC, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO–College of American Pathologists Guideline Update. J Clin Oncol. 2023;41(22):3867–72.

Article  CAS  PubMed  Google Scholar